SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:umu-41560"
 

Sökning: id:"swepub:oai:DiVA.org:umu-41560" > A selective endothe...

  • Weber, Michael AState University of New York, Downstate College of Medicine, New York, NY, USA (författare)

A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension : a randomised, double-blind, placebo-controlled trial

  • Artikel/kapitelEngelska2009

Förlag, utgivningsår, omfång ...

  • Elsevier,2009
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:umu-41560
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-41560URI
  • https://doi.org/10.1016/S0140-6736(09)61500-2DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • BackgroundHypertension cannot always be adequately controlled with available drugs. We investigated the blood-pressure-lowering effects of the new vasodilatory, selective endothelin type A antagonist, darusentan, in patients with treatment-resistant hypertension.MethodsThis randomised, double-blind study was undertaken in 117 sites in North and South America, Europe, New Zealand, and Australia. 379 patients with systolic blood pressure of 140 mm Hg or more (≥130 mm Hg if patient had diabetes or chronic kidney disease) who were receiving at least three blood-pressure-lowering drugs, including a diuretic, at full or maximum tolerated doses were randomly assigned to 14 weeks' treatment with placebo (n=132) or darusentan 50 mg (n=81), 100 mg (n=81), or 300 mg (n=85) taken once daily. Randomisation was made centrally via an automated telephone system, and patients and all investigators were masked to treatment assignments. The primary endpoints were changes in sitting systolic and diastolic blood pressures. Analysis was by intention to treat. The study is registered with ClinicalTrials.gov, number NCT00330369.FindingsAll randomly assigned participants were analysed. The mean reductions in clinic systolic and diastolic blood pressures were 9/5 mm Hg (SD 14/8) with placebo, 17/10 mm Hg (15/9) with darusentan 50 mg, 18/10 mm Hg (16/9) with darusentan 100 mg, and 18/11 mm Hg (18/10) with darusentan 300 mg (p<0·0001 for all effects). The main adverse effects were related to fluid accumulation. Oedema or fluid retention occurred in 67 (27%) patients given darusentan compared with 19 (14%) given placebo. One patient in the placebo group died (sudden cardiac death), and five patients in the three darusentan dose groups combined had cardiac-related serious adverse events.InterpretationDarusentan provides additional reduction in blood pressure in patients who have not attained their treatment goals with three or more antihypertensive drugs. As with other vasodilatory drugs, fluid management with effective diuretic therapy might be needed.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Black, HenryNew York University, New York, NY, USA (författare)
  • Bakris, GeorgeUniversity of Chicago, Chicago, IL, USA (författare)
  • Krum, HenryMonash University, Clayton, VIC, Australia (författare)
  • Linas, StuartDenver Health Medical Center, Denver, CO, USA (författare)
  • Weiss, RobertMaine Research Associates, Auburn, ME, USA (författare)
  • Linseman, Jennifer VGilead Sciences, Foster City, CA, USA (författare)
  • Wiens, Brian LGilead Sciences, Foster City, CA, USA (författare)
  • Warren, Marshelle SGilead Sciences, Foster City, CA, USA (författare)
  • Lindholm, Lars H.Umeå universitet,Allmänmedicin,Umeå University Hospital, Umeå, Sweden(Swepub:umu)lali0003 (författare)
  • State University of New York, Downstate College of Medicine, New York, NY, USANew York University, New York, NY, USA (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:The Lancet: Elsevier374:9699, s. 1423-14310140-67361474-547X

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy